Safety data is clean but the sentinel cohort is too small for efficacy conclusions. The main cohort readout in 2027 is the key catalyst. Monitor for any early efficacy signals or regulatory interactions in the interim.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $0.5500entry
- T+1 · 4mo ago +0.04%α +0.35% · $0.5502
- T+5 · 4mo ago 0.00%α −0.55% · $0.5500
- T+20 · 4mo ago +9.09%α +5.93% · $0.6000
- T+60 · 7w ago −18.18%α −21.27% · $0.4500
Price Chart
How similar events traded
Executive Summary
Vaxart reported topline 12-month safety data from the 400-participant sentinel safety cohort of its Phase 2b oral pill COVID-19 vaccine trial. No vaccine-related serious adverse events or sustained Grade 3+ adverse events were observed in either the oral vaccine or mRNA comparator arms. The complete study data, including the ~5,000-participant main cohort, is anticipated in 2027.
Key Facts
- Topline 12-month safety data from ~400-participant sentinel safety cohort of Phase 2b oral pill COVID-19 vaccine trial
- No vaccine-related serious adverse events (SAEs) or sustained Grade 3+ adverse events in either arm
- 201 participants received oral pill vaccine; 199 received approved mRNA vaccine targeting XBB strain
- Most common AEs in oral vaccine arm: malaise/fatigue (20.9%), headache (18.9%), anorexia (10.0%)
- Most common AEs in mRNA arm: injection site pain (60.3%), injection site tenderness (40.2%), malaise/fatigue (35.2%)
- Symptomatic COVID occurred in 33 oral vaccine recipients vs 30 mRNA recipients; cohort not powered for efficacy
- Complete study data (sentinel + ~5,000 main cohort) expected in 2027
- Project NextGen/BARDA award valued at up to $344.8 million
Financial Impact
No financial data reported; BARDA award up to $344.8 million referenced but no current revenue or earnings impact
Risk Factors
- Efficacy may not replicate in the larger main cohort
- Complete study data not expected until 2027, creating a long wait for a pivotal catalyst
- Competition from approved mRNA and other COVID vaccines
- Reliance on BARDA funding which could be modified or terminated
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-022876 |
| Exhibit: ex_985231.htm | 0001437749-26-022876 |
| Document: 0001437749-26-022876-index-headers.html | 0001437749-26-022876 |
| Document: 0001437749-26-022876-index.html | 0001437749-26-022876 |
| Document: 0001437749-26-022876.txt | 0001437749-26-022876 |
Track record
23 reports on VXRT
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +37.66% at T+60 after the May 1, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $0.3700 Now $0.3600 +2.70% settles Feb 4
- Oct 19, 202628d ago 8-K Neutral 3/10 Entry $0.4900 Now $0.3600 −26.53% settles Jan 15
- Jul 28, 202615w ago 8-K Neutral 2/10 Entry $0.4800 to $0.4900 Now $0.3600 −25.00% ▲ +2.08% −2.53% vs SPY
- Jul 7, 202618w ago 8-K Neutral 4/10 Viewing Entry $0.5500 to $0.4500 Now $0.3600 −34.55% ▼ −18.18% −21.27% vs SPY
- Jul 6, 202619w ago DEFA14A Neutral 5/10 Entry $0.6200 to $0.4540 Now $0.3600 −41.94% ▼ −26.77% −28.93% vs SPY
- Jul 2, 202619w ago DEFA14A Bullish 5/10 Entry $0.6400 to $0.4500 Now $0.3600 −43.75% ▼ −29.69% −33.51% vs SPY
- Jul 2, 202619w ago 8-K Neutral 4/10 Entry $0.6400 to $0.4520 Now $0.3600 −43.75% ▼ −29.38% −32.80% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 4/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago DEFA14A Neutral 3/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
- Jun 26, 202620w ago 8-K Mixed 5/10 Entry $0.5700 to $0.4900 Now $0.3600 −36.84% ▼ −14.04% −17.08% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers